1 Introduction The importance of understanding the contribution of ethnic differences in drug pharmacokinetics (PK) and how these may impact on dose and drug–drug interaction (DDI) liability is well known [1]. The USA is an increasingly diverse population; latest census data indicates that 57.8% are white, 18.7% Hispanic or Latino, 12.1% African American, and 11.4% other ethnicities [2].
Trevor Johnson
Get in touch with Trevor
Contact Trevor, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack